Cargando…

Ebola virus glycoprotein stimulates IL-18–dependent natural killer cell responses

BACKGROUND: NK cells are activated by innate cytokines and viral ligands to kill virus-infected cells. These functions are enhanced during secondary immune responses and after vaccination by synergy with effector T cells and virus-specific antibodies. In human Ebola virus infection, clinical outcome...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wagstaffe, Helen R., Clutterbuck, Elizabeth A., Bockstal, Viki, Stoop, Jeroen N., Luhn, Kerstin, Douoguih, Macaya, Shukarev, Georgi, Snape, Matthew D., Pollard, Andrew J., Riley, Eleanor M., Goodier, Martin R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2020
Materias:	Clinical Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324188/ https://www.ncbi.nlm.nih.gov/pubmed/32315287 http://dx.doi.org/10.1172/JCI132438

Ejemplares similares

Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination
por: Wagstaffe, Helen R, et al.
Publicado: (2019)

Durable natural killer cell responses after heterologous two-dose Ebola vaccination
por: Wagstaffe, Helen R., et al.
Publicado: (2021)

A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks
por: Shukarev, Georgi, et al.
Publicado: (2016)

NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans
por: Wagstaffe, Helen R., et al.
Publicado: (2022)

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen
por: Bockstal, Viki, et al.
Publicado: (2021)

Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya
por: Mutua, Gaudensia, et al.
Publicado: (2019)

Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study
por: Goldstein, Neil, et al.
Publicado: (2020)

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
por: Anywaine, Zacchaeus, et al.
Publicado: (2019)

Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Alexandre, Marie, et al.
Publicado: (2023)

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Bockstal, Viki, et al.
Publicado: (2022)

Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation
por: Pasin, Chloé, et al.
Publicado: (2019)

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study
por: Bockstal, Viki, et al.
Publicado: (2022)

Vaccinating for natural killer cell effector functions
por: Wagstaffe, Helen R, et al.
Publicado: (2018)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
por: Barry, Houreratou, et al.
Publicado: (2021)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
por: Anywaine, Zacchaeus, et al.
Publicado: (2022)

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
por: Roozendaal, Ramon, et al.
Publicado: (2020)

IL-15 Promotes Polyfunctional NK Cell Responses to Influenza by Boosting IL-12 Production
por: Wagstaffe, Helen R., et al.
Publicado: (2018)

The Ebola-Glycoprotein Modulates the Function of Natural Killer Cells
por: Edri, Avishay, et al.
Publicado: (2018)

Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone
por: Manno, Daniela, et al.
Publicado: (2022)

Ebola virus shed glycoprotein is toxic to human T, B, and natural killer lymphocytes
por: Perez-Valencia, Luis J., et al.
Publicado: (2023)

EBOVAC-Salone: Lessons learned from implementing an Ebola vaccine trial in an Ebola-affected country
por: Mooney, Thomas, et al.
Publicado: (2018)

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
por: Afolabi, Muhammed O, et al.
Publicado: (2022)

Ebola, the killer virus
por: Ghazanfar, Haider, et al.
Publicado: (2015)

Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans
por: McLean, Chelsea, et al.
Publicado: (2023)

Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo
por: Watson-Jones, Deborah, et al.
Publicado: (2022)

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
por: Ishola, David, et al.
Publicado: (2022)

Accessing Maternal Health Services in Eastern Burma
por: Douoguih, Macaya
Publicado: (2008)

Natural Killer Cells Dampen the Pathogenic Features of Recall Responses to Influenza Infection
por: Mooney, Jason P., et al.
Publicado: (2020)

Differential activation of CD57-defined natural killer cell subsets during recall responses to vaccine antigens
por: White, Matthew J, et al.
Publicado: (2014)

Ebola: Profile of a Killer Virus
por: Morse, Stephen S.
Publicado: (2017)

Recombinant Antibodies to the Ebola Virus Glycoprotein
por: Panina, A. A., et al.
Publicado: (2017)

Steric Shielding of Surface Epitopes and Impaired Immune Recognition Induced by the Ebola Virus Glycoprotein
por: Francica, Joseph R., et al.
Publicado: (2010)

Acute Disruption of Bone Marrow B Lymphopoiesis and Apoptosis of Transitional and Marginal Zone B Cells in the Spleen following a Blood-Stage Plasmodium chabaudi Infection in Mice
por: Bockstal, Viki, et al.
Publicado: (2011)

Activation of Natural Killer Cells during Microbial Infections
por: Horowitz, Amir, et al.
Publicado: (2012)

Impact of prophylactic vaccination strategies on Ebola virus transmission: A modeling analysis
por: Potluri, Ravi, et al.
Publicado: (2020)

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment()
por: Custers, Jerome, et al.
Publicado: (2021)

LB7. Ad26.COV2.S-Elicted Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials
por: Le Gars, Mathieu, et al.
Publicado: (2021)

An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells
por: Cai, Yingyun, et al.
Publicado: (2021)

Regulation of the human NK cell compartment by pathogens and vaccines
por: Goodier, Martin R, et al.
Publicado: (2021)

1049. Minimal Transient HIV-1 Viremia Following Vaccination Regimens Containing AD26. ZEBOV and MVA-BN-Filo in ART-Suppressed People Living with HIV
por: Custer, Benjamin L, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_titdjdl62ktg5sib2qeqgmuoos